SheenaKAuroraMD

Neurology • Stanford, CA

Headache, Pain Medicine

Adjunct Clinical Associate Professor, Stanford University. Medical Fellow, Global Launch Leader Pain, Eli Lilly and Company.

Join to view full profile

Dr. Aurora is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Aurora's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Fax+1 650-498-5840

Summary

Dr. Sheena Aurora is a neurologist in Palo Alto, CA and is affiliated with Stanford Health Care. She received her medical degree from Christian Medical College Ludhiana and has been in practice 28 years. She specializes in headache and pain medicine and is experienced in headache medicine, migraine disorders, pain management, headache disorders, and botulinum toxin injections for headache. She has more than 100 publications and over 500 citings.

Education & Training

Christian Medical College LudhianaClass of 1989

Certifications & Licensure

CA State Medical License 2012 - 2025
WA State Medical License 2000 - 2025
IN State Medical License 2017 - 2021
MI State Medical License 1995 - 2002
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors Castle Connolly, 2009-2012
Women's Health Castle Connolly, 2008
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Does Topiramate Adjust the Excitability of the Brain in Migraine Sufferers? Start of enrollment: 2006 Feb 01
Unknown status
Study of Lornoxicam or Placebo for Acute Treatment of the Headache of Migraine. Start of enrollment: 2005 Dec 01
Completed
Phase 2
A Study of a Melatonin Receptor Agonist to Prevent Migraine Start of enrollment: 2008 Apr 01
Terminated
Phase 2
A Study of Galcanezumab in Participants With Chronic Cluster Headache Start of enrollment: 2015 Jun 18
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

Cardiovascular safety of dihydroergotamine mesylate delivered by precision olfactory delivery (INP104) for the acute treatment of migraine.
Rima M Dafer, Gretchen E Tietjen, John F Rothrock, Robert E Vann, Stephen B Shrewsbury
Headache. 2024-09-01
The Gut-brain Connection and Episodic Migraine: an Update.
Linda Nguyen, Nada Hindiyeh, Sutapa Ray, Robert E Vann, Sheena K Aurora
Current Pain and Headache Reports. 2023-11-01
1 citations
Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective s...
Victor S Wang, Justin Kosman, Hsiangkuo Yuan, Clinton Lauritsen, Stephen Shrewsbury
Headache. 2023-10-01

Lectures

25th Annual Practicing Physicians Approach to the Difficult Headache Patient
Diamond Headache Clinic Reseach and Educational Foundation, Rancho Mirage, California - 2/17/2012

Press Mentions

Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray Is Safe to Use When Co-Administered with Commonly Prescribed Migraine MedicationsApril 26th, 2023
Why the Key to Stopping Your Migraine Attack May Be Right Under Your NoseJune 2nd, 2022
Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of NeurologyMarch 22nd, 2022
Join now to see all

Professional Memberships

American Academy of Neurology - AAN
Member